Pliant Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Pliant Therapeutics
PLRX Stock  USD 1.69  0.01  0.59%   
Pliant Therapeutics financial statements provide useful quarterly and yearly information to potential Pliant Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pliant Therapeutics financial statements helps investors assess Pliant Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pliant Therapeutics' valuation are summarized below:
Market Capitalization
104.1 M
Enterprise Value Revenue
1.4 K
Earnings Share
(3.47)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available trending fundamental ratios for Pliant Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pliant Therapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 509.1 M in 2025. Enterprise Value is likely to drop to about 473.5 M in 2025

Pliant Therapeutics Total Revenue

1.58 Million

Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 22.1 M, Net Interest Income of 19 M or Interest Income of 22.1 M, as well as many indicators such as Price To Sales Ratio of 636, Dividend Yield of 0.0 or PTB Ratio of 2.75. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pliant Therapeutics Correlation against competitors.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Pliant Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets270.7 M396.9 M142.8 M
Slightly volatile
Total Current Liabilities17.9 M33.2 M10.7 M
Slightly volatile
Other Liabilities717.5 K995.9 K441.3 K
Slightly volatile
Accounts Payable3.1 M6 M2.3 M
Slightly volatile
Cash58 M71.2 M31.8 M
Slightly volatile
Cash And Short Term Investments251.2 M355.7 M131.7 M
Slightly volatile
Net Receivables3.8 M3.4 M2.1 M
Slightly volatile
Total Liabilities54.1 M92.9 M29.4 M
Slightly volatile
Total Current Assets259.4 M362.3 M136.2 M
Slightly volatile
Common Stock3.6 K6.9 K2.3 K
Slightly volatile
Property Plant Equipment5.5 M5.2 M3.6 M
Slightly volatile
Short and Long Term Debt Total31.5 M30 M6.3 M
Slightly volatile
Other Current Liabilities15 M26.2 M8.2 M
Slightly volatile
Property Plant And Equipment Net34.4 M32.8 M8.7 M
Slightly volatile
Non Current Assets Total36.4 M34.7 M9.7 M
Slightly volatile
Non Currrent Assets Other1.4 M1.9 M925.8 K
Slightly volatile
Other Assets0.860.9599.5 K
Pretty Stable
Common Stock Total Equity6 K5.8 K2.4 K
Slightly volatile
Common Stock Shares Outstanding44.7 M60.5 M28.8 M
Slightly volatile
Liabilities And Stockholders Equity308.3 M396.9 M175.2 M
Slightly volatile
Non Current Liabilities Total30 M59.6 M49.5 M
Slightly volatile
Capital Lease Obligations31.5 M30 M5.1 M
Slightly volatile
Other Current Assets5.5 M6.5 M2.7 M
Slightly volatile
Other Stockholder Equity543.6 M1 B250.7 M
Slightly volatile
Deferred Long Term Liabilities1.6 M3.2 M1.3 M
Slightly volatile
Capital Stock5.1 K5.4 K44.4 M
Slightly volatile
Non Current Liabilities Other4.1 M3.9 M1.3 M
Slightly volatile
Net Working Capital275.7 M329 M155.2 M
Slightly volatile
Property Plant And Equipment Gross45.8 M43.6 M11.9 M
Slightly volatile
Capital Surpluse538.6 M751.8 M463.9 M
Slightly volatile
Inventory0.80.90.9813
Slightly volatile
Short Term Debt1 M1.1 M3.3 M
Slightly volatile
Long Term Debt18.4 M30.2 M11.7 M
Slightly volatile
Long Term Debt Total7.9 M8.9 M9.7 M
Slightly volatile

Pliant Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income19 M18.1 M4.2 M
Slightly volatile
Interest Income22.1 M21.1 M4.8 M
Slightly volatile
Depreciation And Amortization1.9 M2.1 M1.2 M
Slightly volatile
Selling General Administrative34.4 M59.1 M19.1 M
Slightly volatile
Other Operating Expenses224.3 M213.6 M75.5 M
Slightly volatile
Research Development95.8 M169.3 M56.3 M
Slightly volatile
Total Operating Expenses118 M228.4 M69.8 M
Slightly volatile
Reconciled Depreciation1.6 M2.1 M1.1 M
Slightly volatile
Gross Profit1.4 M1.4 M39.4 M
Slightly volatile
Non Operating Income Net Other4.7 M4.5 M1.2 M
Slightly volatile
Cost Of Revenue2.3 M1.7 M3 M
Slightly volatile

Pliant Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock260.4 M248 M90.7 M
Slightly volatile
Depreciation1.5 M2.1 M888.8 K
Slightly volatile
Capital Expenditures2 M3.8 M1.7 M
Slightly volatile
Total Cash From Financing Activities22 M23.1 M65.9 M
Slightly volatile
End Period Cash Flow58.4 M72.7 M32 M
Slightly volatile
Change To Netincome27.3 M26 M7.2 M
Slightly volatile
Stock Based Compensation19 M37.6 M8.9 M
Slightly volatile
Begin Period Cash Flow55.3 M64.7 M27.6 M
Slightly volatile
Issuance Of Capital Stock3 M3.2 M96.8 M
Very volatile
Change To Inventory96.6 K101.7 K2 M
Slightly volatile
Net Borrowings7.9 M8.9 M9.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio636606138
Slightly volatile
Days Sales Outstanding654623168
Slightly volatile
Stock Based Compensation To Revenue26.6125.345.2643
Slightly volatile
Capex To Depreciation2.051.81083.1635
Slightly volatile
EV To Sales605576131
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-41.0E-4
Slightly volatile
Payables Turnover2.22.10.9076
Slightly volatile
Sales General And Administrative To Revenue34.6533.07.1504
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue76.4472.816.2661
Slightly volatile
Capex To Revenue0.550.520.1436
Slightly volatile
Cash Per Share4.745.8765.5754
Slightly volatile
Days Payables Outstanding171180899
Slightly volatile
Income Quality1.390.73941.1231
Very volatile
Net Debt To EBITDA0.170.180445.6152
Very volatile
Current Ratio10.7710.90578.0492
Slightly volatile
Receivables Turnover0.580.615.757
Slightly volatile
Capex Per Share0.06040.06360.9022
Slightly volatile
Revenue Per Share0.02940.03091.1096
Slightly volatile
Interest Debt Per Share0.890.84350.1797
Slightly volatile
Debt To Assets0.07930.07550.0206
Slightly volatile
Operating Cycle654623168
Slightly volatile
Days Of Payables Outstanding171180899
Slightly volatile
Ebt Per Ebit0.730.92090.9353
Slightly volatile
Quick Ratio10.7710.90578.0492
Slightly volatile
Cash Ratio2.042.14313.0263
Pretty Stable
Days Of Inventory Outstanding1.0E-41.0E-41.0E-4
Slightly volatile
Days Of Sales Outstanding654623168
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.191.02471.0878
Very volatile
Fixed Asset Turnover0.360.389.5179
Slightly volatile
Debt Ratio0.07930.07550.0206
Slightly volatile
Price Sales Ratio636606138
Slightly volatile
Asset Turnover0.00340.00350.3128
Slightly volatile
Gross Profit Margin0.480.560.5751
Pretty Stable

Pliant Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap509.1 M797.3 M357.5 M
Slightly volatile
Enterprise Value473.5 M756.1 M331.1 M
Slightly volatile

Pliant Fundamental Market Drivers

Cash And Short Term Investments355.7 M

Pliant Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue1.7 M2.3 M
Stock Based Compensation To Revenue 25.34  26.61 
Sales General And Administrative To Revenue 33.00  34.65 
Research And Ddevelopement To Revenue 72.80  76.44 
Capex To Revenue 0.52  0.55 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(134.03)(127.33)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY